Pediatric Omeprazole Dosing Guidelines

FDA-Approved Dosing by Indication

• The American Academy of Pediatrics recommends omeprazole 10 mg once daily for children weighing 10 to <20 kg for treatment of symptomatic GERD in children 2-16 years 1
• The American Academy of Pediatrics recommends omeprazole 20 mg once daily for children weighing ≥20 kg for treatment of symptomatic GERD in children 2-16 years 1
• The American Academy of Pediatrics recommends omeprazole 10 mg once daily for children weighing 10 to <20 kg for treatment of erosive esophagitis due to acid-mediated GERD in children 2-16 years 1
• The American Academy of Pediatrics recommends omeprazole 20 mg once daily for children weighing ≥20 kg for treatment of erosive esophagitis due to acid-mediated GERD in children 2-16 years 1

Dosing for Special Conditions

• For eosinophilic esophagitis in children, initial treatment is omeprazole 1 mg/kg twice daily (up to 40 mg twice daily) 1
• For eosinophilic esophagitis in children, maintenance therapy is 1 mg/kg/day (maximum 40 mg/day) 2, 3
• For severe or refractory GERD in infants under 2 years, starting dose is 0.7 mg/kg/day 1
• For severe or refractory GERD in infants under 2 years, dose may be escalated up to 1.4-2.8 mg/kg/day in divided doses 1

Administration Instructions

• For children unable to swallow capsules, omeprazole can be administered by mixing pellets with applesauce 1

Clinical Considerations

• Omeprazole has demonstrated superior efficacy compared to H2-receptor antagonists for pediatric GERD 1
• Long-term use (>2.5 years) of omeprazole may be associated with enterochromaffin cell hyperplasia in up to 50% of children 1

Monitoring

• For long-term therapy, monitor for potential side effects including headaches, diarrhea, and nausea 1

Omeprazole Dosage and Preparation for Infants

Preparation and Administration

• The American Academy of Pediatrics recommends preparing a compounded suspension from omeprazole capsules, which can be mixed with applesauce or compounded into a 6 mg/mL suspension by a retail pharmacy 4, 5
• For a 3 mg daily dose using 6 mg/mL suspension, administer 0.5 mL daily, as recommended by the American Academy of Pediatrics 4
• A 30-day supply can be prepared using two 20 mg capsules to create approximately 6.7 mL of 6 mg/mL suspension, providing 40 mg total—sufficient for 13 days, according to the American Academy of Pediatrics 4

Omeprazole Dosing for Eosinophilic Esophagitis in Children

Standard and Higher Dosing Regimens

• For a 16 kg child with eosinophilic esophagitis, the maximum dose of omeprazole is 20 mg twice daily (total 40 mg/day) 6
• The initial treatment for eosinophilic esophagitis is 1 mg/kg twice daily (up to maximum 40 mg twice daily), which calculates to 16 mg twice daily (32 mg/day total) for a 16 kg child 6
• The higher dosing regimen (omeprazole 20 mg twice daily or equivalent) has demonstrated superior response rates (50.8%) compared to standard doses (35.8%) for eosinophilic esophagitis 6
• Treatment duration for eosinophilic esophagitis should be 8-12 weeks before assessing histological response 6

Omeprazole Dosing for Pediatric Patients

Pharmacokinetics and Dosing Considerations

• Infants have prolonged elimination half-lives (55-90 hours vs. 30 hours in adults) and altered volumes of distribution, necessitating a weight-based approach rather than extrapolating adult doses 7

Clinical Response and Dose Titration

• Approximately 50% of infants may require doses higher than the initial 0.7 mg/kg/day to achieve adequate acid control, and dose titration is essential based on clinical response and pH monitoring when available 7

Weight-Based Omeprazole Dosing for Infants

Special Considerations for Neonates and Premature Infants

• Weight-based dosing recommendations for term infants should NOT be extrapolated to premature infants due to immature renal function and risk of drug accumulation, as stated by the Pediatrics guideline society 8

Efficacy and Safety of Omeprazole in Pediatric Gastro‑Esophageal Reflux Disease

Comparative Efficacy

• Omeprazole provides superior healing of erosive esophagitis and greater symptom relief than H₂‑receptor antagonists in children with gastro‑esophageal reflux disease. 9

Long‑Term Safety Concerns

• Up to half of children receiving proton‑pump inhibitors for more than 2.5 years may develop enterochromaffin‑cell hyperplasia. 9
• Headache, diarrhea, constipation, and nausea occur in roughly one‑quarter of pediatric patients (≈ 14 % overall) on prolonged omeprazole therapy. 9
• Acid suppression in infants is associated with an increased risk of lower respiratory‑tract infections. 9

Clinical Use Recommendations

• Placebo‑controlled trials in infants with uncomplicated reflux show no benefit of proton‑pump inhibitors over placebo for reducing irritability; therefore, omeprazole should not be used routinely in this population. 9
• Omeprazole should be reserved for children with documented erosive esophagitis or severe, refractory gastro‑esophageal reflux symptoms. 9